August 04, 2017
In Re: Epipen (Epinephrine Injection, USP) Marketing, Sales Practices and Antitrust Litigation
Case Number:
2:17-md-02785
Court:
Nature of Suit:
Multi Party Litigation:
Class Action, Multi-district Litigation
Judge:
Firms
- Burns Charest
- Squitieri & Fearon
- Law Offices of Ursula Taylor
- Matthew G. Miller PC
- Gustafson Gluek
- Fredrikson & Byron
- Foulston Siefkin
- Weil Gotshal
- Sidley Austin
- Sharp Law LLP
- Parker Waichman
- Gibson Dunn
- Siegfried & Jensen
- Spragens Law
- Spencer Fane
- Holland & Knight
- DLA Piper
- Wilson Sonsini
- Foley & Lardner
- Lockridge Grindal
- Pritzker Levine
- DiCello Levitt
- Blood Hurst
- Berkowitz Oliver
- Saiber LLC
- Hogan Lovells
- Joseph Saveri Law Firm
- King & Spalding
- Barton & Burrows
- Kaufman & Canoles
- Robbins Geller
- Goldman Scarlato
- Robbins Russell
- Kramer Levin
- Perkins Coie
- Yarmuth LLP
- Pallas Partners
- Lanier Law Firm
- Groom Law Group
- Williams & Connolly
- Hagens Berman
- Horn Aylward
- Lightfoot Franklin
- Hinkle Law Firm
- Reed Smith
- Robins Kaplan
- Carella Byrne
- Marion's Inn
- Shook Hardy
- Goodwin Procter
- Strategic Health Law
- Dollar Burns
- Keller Rohrback
- Butler Prather
- Bradford & Wilson
- Bush Seyferth
- Wagstaff & Cartmell
- Mehri & Skalet
- Lowey Dannenberg
- Steven Williams Law
- Levi & Korsinsky
- Gibbons PC
- Beasley Allen
- Berman Tabacco
- Boies Schiller
- Ali & Lockwood
- Clark Hill
- Lathrop GPM
- GM Law PC
- Baron & Budd
- Latham & Watkins
- Mayer Brown
- White & Case
- Willkie Farr
Companies
- Amerigroup Corp.
- Change Healthcare Inc.
- MedImpact Healthcare Systems Inc.
- Humana Inc.
- UnitedHealth Group Inc.
- Blue Cross Blue Shield Association
- Meridian Medical Technologies Inc.
- Coventry Health Care Inc.
- Express Scripts Holding Co.
- The Segal Co. Inc.
- Viatris Inc.
- CVS Health Corp.
- Aetna Inc.
- OptumRx Inc.
- Centene Corp.
- King Pharmaceuticals Inc.
- Optum Inc.
- Sanofi
- Pfizer Inc.
- Teva Pharmaceutical Industries Ltd.
Sectors & Industries:
View recent docket activity
Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.
Coverage
-
March 14, 2022
Judge OKs $264M Deal Ending Mylan EpiPen Price-Hike Suit
A Kansas federal court has preliminarily approved a $264 million deal that would end claims that Mylan colluded with Pfizer Inc. to obstruct generic versions of the EpiPen, the emergency drug used to treat severe allergic reactions, from entering the market.
Parties
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
- Direct access to case information and documents.
- All significant new filings across U.S. federal district courts, updated hourly on business days.
- Full-text searches on all patent complaints in federal courts.
- No-fee downloads of the complaints and so much more!
TRY LAW360 FREE FOR SEVEN DAYS
Already a subscriber? Click here to login